 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C19H21N |
| Molar mass | 263.384 g·mol−1 |
Pridefine (AHR-1,118) is a drug which was investigated as an antidepressant in the late 1970s and early 1980s, but was never marketed.[1] It acts as a balanced reuptake inhibitorofserotonin, dopamine, and norepinephrine, and also has some weak releasing activity.[1][2][3]
Inclinical trials pridefine was found to be as efficacious as the tricyclic antidepressants amitriptyline and imipramine in the treatment of major depressive disorder but was much more tolerable in comparison and also had an earlier onset of action.[1] It has been shown to be effective in the treatment of alcoholism as well.[1]
|
| |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
|
Treatment of drug dependence (N07B)
| |
|---|---|
| Nicotine dependence |
|
| Alcohol dependence |
|
| Opioid dependence |
|
| Benzodiazepine dependence |
|
|
| |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DRAsTooltip Dopamine releasing agents |
| ||||||||||||||
| NRAsTooltip Norepinephrine releasing agents |
| ||||||||||||||
| SRAsTooltip Serotonin releasing agents |
| ||||||||||||||
| Others |
| ||||||||||||||
See also: Receptor/signaling modulators • Monoamine reuptake inhibitors • Adrenergics • Dopaminergics • Serotonergics • Monoamine metabolism modulators • Monoamine neurotoxins | |||||||||||||||
